← 產業報告目錄
Hematological Malignancies Drugs Market Size, Share & Trends Analysis Report By Drugs (Monoclonal Antibodies, CAR-T Cell Therapy), By Pipeline Products, By Indication (Leukemia, Lymphoma), By Region, And Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-11頁數 180報告編號 INSIGHTACE-c0132bcbbb
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The global Hematological Malignancies Drugs Market is set to witness considerable expansion over the coming years.
Hematological Malignancies Drugs encompasses cancers that most often start in the bone marrow or the immune system cells. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is driven by expanding appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Hematological Malignancies Drugs Market Snapshot
Chapter 4. Global Hematological Malignancies Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis
5.1. By Drugs, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drugs:
5.2.1. Monoclonal Antibodies
5.2.1.1. Blincyto (Blinatumomab)
5.2.1.2. Besponsa (Inotuzumab Ozogamicin)
5.2.1.3. Lumoxiti (Moxetumomab Pasudotox)
5.2.1.4. Mylotarg (Gemtuzumab Ozogamicin)
5.2.1.5. Opdivo (Nivolumab)
5.2.1.6. AiRuiKa (Camrelizumab)
5.2.1.7. Tyvyt (Sintilimab)
5.2.1.8. Tislelizumab
5.2.1.9. Gazyva (Obinutuzumab)
5.2.1.10. Zynlonta (Loncastuximab Tesirine-lpyl)
5.2.1.11. Darzalex (Daratumumab)
5.2.1.12. Blenrep (Belantamab Mafodotin-blmf)
5.2.1.13. Keytruda (Pembrolizumab)
5.2.1.14. Adcetris (Brentuximab Vedotin)
5.2.1.15. Arzerra (Ofatumumab)
5.2.2. CAR-T Cell Therapy
5.2.2.1. Tecartus (Brexucabtagene Autoleucel)
5.2.2.2. Kymriah (Tisagenlecleucel)
5.2.2.3. Yescarta (Axicabtagene Ciloleucel)
5.2.2.4. Breyanzi (Lisocabtagene Maraleucel)
5.2.2.5. Abecma (Idecabtagene Vicleucel)
Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis
6.1. By Pipeline Products & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Pipeline Products:
6.2.1. Monoclonal Antibodies
6.2.1.1. Teclistamab
6.2.1.2. Iomab-B
6.2.1.3. Ublituximab
6.2.1.4. CS1001
6.2.2. CAR-T Cell Therapy
6.2.2.1. Ciltacabtagene Autoleucel (JNJ-68284528)
Chapter 7. Market Segmentation 3: By Pipeline Products Estimates & Trend Analysis
7.1. By Indications & Market Share, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Indications:
7.2.1. Leukemia
7.2.1.1. Acute Lymphoblastic Leukemia
7.2.1.2. Chronic Lymphoblastic Leukemia
7.2.1.3. Acute Myeloid Leukemia
7.2.2. Lymphoma
7.2.2.1. Hodgkin's Lymphoma
7.2.2.2. Non-Hodgkin's Lymphoma
7.2.3. Multiple Myeloma
Chapter 8. Hematological Malignancies Drugs Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Drugs, 2024-2031
8.1.2. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Pipeline Products, 2024-2031
8.1.3. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2024-2031
8.1.4. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.2.2. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.2.3. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.2.4. Europe Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.3.2. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.3.3. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.3.4. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.4.2. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.4.3. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.4.4. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031
8.5.2. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031
8.5.3. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031
8.5.4. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AbbVie Inc.
9.2.2. Amgen Inc.
9.2.3. Bristol-Myers Squibb Company
9.2.4. F. Hoffmann-La Roche Ltd.
9.2.5. Gilead Sciences, Inc.
9.2.6. GlaxoSmithKline plc
9.2.7. Immune-Onc Therapeutics, Inc.
9.2.8. Johnson & Johnson Services, Inc.
9.2.9. Merck & Co., Inc.
9.2.10. Novartis International AG
9.2.11. Pfizer Inc.
9.2.12. Sanofi S.A.
9.2.13. Takeda Pharmaceutical Company Limited
9.2.14. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們